Combined Prognostic Value of Preprocedural Protein-Energy Wasting and Inflammation Status for Amputation and/or Mortality after Lower-Extremity Revascularization in Hemodialysis Patients with Peripheral Arterial Disease

J Clin Med. 2023 Dec 25;13(1):126. doi: 10.3390/jcm13010126.

Abstract

Protein-energy wasting is associated with inflammation and advanced atherosclerosis in hemodialysis patients. We enrolled 800 patients who had undergone successful lower-extremity revascularization, and we investigated the association among the Geriatric Nutritional Risk Index (GNRI) as a surrogate marker of protein-energy wasting, C-reactive protein (CRP), and their joint roles in predicting amputation and mortality. They were divided into lower, middle, and upper tertiles (T1, T2, and T3) according to GNRI and CRP levels, respectively. Regarding the results, the amputation-free survival rates over 8 years were 47.0%, 56.9%, and 69.5% in T1, T2, and T3 of the GNRI and 65.8%, 58.7%, and 33.2% for T1, T2, and T3 of CRP, respectively (p < 0.0001 for both). A reduced GNRI [adjusted hazard ratio (aHR) 1.78, 95% confidence interval (CI) 1.24-2.59, p = 0.0016 for T1 vs. T3] and elevated CRP (aHR 1.86, 95% CI 1.30-2.70, p = 0.0007 for T3 vs. T1) independently predicted amputation and/or mortality. When the two variables were combined, the risk was 3.77-fold higher (95% CI 1.97-7.69, p < 0.0001) in patients who occupied both T1 of the GNRI and T3 of CRP than in those who occupied both T3 of the GNRI and T1 of CRP. In conclusion, patients with preprocedurally decreased GNRI and elevated CRP levels frequently experienced amputation and mortality, and a combination of these two variables could more accurately stratify the risk.

Keywords: C-reactive protein; geriatric nutritional risk index; hemodialysis; lower-extremity revascularization; peripheral artery disease.

Grants and funding

H. Izawa received grant support through his institution from Bayer, Sumitomo Pharma, PDR Pharma, Biotronik Japan, Abbott Japan, Boston Scientific Japan, Japan Lifeline, and Medtronic Japan and honoraria for lectures from Otsuka, Novartis, Eli Lilly Japan, Bayer, Nippon Boehringer Ingelheim and Daiichi Sankyo. T.M. received lecture fees from Bayer Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Dainippon Sumitomo Pharma Co., Ltd.; Kowa Co., Ltd.; MSD K.K.; Mitsubishi Tanabe Pharma Co.; Nippon Boehringer Ingelheim Co., Ltd.; Novartis Pharma K.K.; Pfizer Japan Inc.; Sanofi-aventis K.K.; and Takeda Pharmaceutical Co., Ltd. T.M. received unrestricted research grants for the Department of Cardiology, Nagoya University Graduate School of Medicine, from Astellas Pharma Inc.; Daiichi Sankyo Co., Ltd.; Dainippon Sumitomo Pharma Co., Ltd.; Kowa Co., Ltd.; MSD K.K.; Mitsubishi Tanabe Pharma Co.; Nippon Boehringer Ingelheim Co., Ltd.; Novartis Pharma K.K.; Otsuka Pharma Ltd.; Pfizer Japan Inc.; Sanofi-aventis K.K.; Takeda Pharmaceutical Co., Ltd.; and Teijin Pharma Ltd. H. Ishii received lecture fees from Astellas Pharma Inc.; Astrazeneca Inc.; Bayer Pharmaceutical Co., Ltd.; Bristol-Myers Squibb Inc.; Chugai Pharmaceutical Co., Ltd.; Daiichi-Sankyo Pharma Inc.; and MSD K.K.